Acute gramine response in ovarian cancer cell lines
Cell-based study · Human SK-OV-3 and OV-90 ovarian cancer cells; IOSE80 ovarian epithelial cells as a viability comparator [1]
A 24-hour concentration-response series reduced CCK-8 viability. At 50 and 100 µM, gramine decreased EdU labeling and PDK1 protein and increased apoptosis-associated readouts. IOSE80 viability also declined; its reported IC50 lies above the tested range. These results do not establish a selective direct molecular target.
| Endpoint | Reported result | Reference |
|---|---|---|
| SK-OV-3 CCK-8 viability at 24 h | IC50 78.63 µM | [1] |
| OV-90 CCK-8 viability at 24 h | IC50 117.2 µM | [1] |
| IOSE80 CCK-8 viability at 24 h; reported estimate exceeds highest tested concentration (200 µM) | reported IC50 393.6 µM | [1] |
| EdU-positive cells and Ki67 protein after 24 h at 50 or 100 µM | reported result EdU labeling decreased; Ki67 reduction was clearer at 100 µM. | [1] |
| TUNEL positivity and Bax/Bcl-2 and cleaved PARP1/PARP1 ratios at 24 h, 50 or 100 µM | reported result TUNEL positivity and apoptosis-associated protein ratios increased versus untreated controls. | [1] |
| PDK1 protein at 24 h, 50 or 100 µM | reported result PDK1 protein decreased in both cancer cell lines. | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- CCK-8: 12.5, 25, 50, 100 and 200 µM; EdU, Ki67, apoptosis and PDK1 readouts: 50 and 100 µM, with 0 µM controls.
- Exposure duration
- 24 h gramine exposure for the adopted endpoints.
- Method
- Addition to cell culture; comparison with untreated/0 µM controls as labeled in the figures.
- Vehicle
- DMSO; final concentration <0.1% (v/v) in all cell culture systems, according to the paper.
- Reported limits
- IC50 fitting model and uncertainty are not specified in the read methods. The reported IOSE80 IC50 exceeds the tested concentration range. Lot-specific applicability to Adooq is not established.
Methods and source locations
Compound reported in the paper: Gramine; Compound label in the paper: HY-N0166, reported purity 99.80% (MedChemExpress)
Compound-level cell-line evidence using another supplier’s material; no verification of an Adooq lot, human efficacy or animal benefit.
Materials and methods: Cell culture and drugs, CCK-8, EdU/TUNEL, western blotting, statistics; Figure 1B,D,E; Figure 2; Figure 4A; Discussion
SK-OV-3 CCK-8 viability at 24 h: CCK-8; 6 replicate wells per group; 3 biological repeats. — Results, first subsection; Figure 1B
OV-90 CCK-8 viability at 24 h: CCK-8; 6 replicate wells per group; 3 biological repeats. — Results, first subsection; Figure 1B
IOSE80 CCK-8 viability at 24 h; reported estimate exceeds highest tested concentration (200 µM): CCK-8. Figure 1B shows the IOSE80 series; the figure caption names only the two cancer lines. Do not interpret the extrapolated estimate as a directly observed 50% endpoint. — Results, first subsection; Figure 1B and Materials and methods, CCK-8
EdU-positive cells and Ki67 protein after 24 h at 50 or 100 µM: EdU microscopy and western blotting; Figure 1 caption reports mean ± SD, three independent experiments. No exact bar heights extracted. — Figure 1D,E and caption; Materials and methods, EdU and western blotting
TUNEL positivity and Bax/Bcl-2 and cleaved PARP1/PARP1 ratios at 24 h, 50 or 100 µM: TUNEL microscopy and western blotting; mean ± SD, three independent experiments as captioned. Responses were not uniformly monotonic across endpoints. — Figure 2A,B and caption; Results, first subsection
PDK1 protein at 24 h, 50 or 100 µM: Western blotting normalized to GAPDH; mean ± SD, three independent experiments as captioned. This is protein abundance, not kinase inhibition or binding. — Figure 4A and caption; Materials and methods, western blotting